key: cord-0862897-74htgl2f authors: Öztop, Nida; Demir, Semra; Beyaz, Şengül; Ünal, Derya; Çolakoğlu, Bahauddin; Büyüköztürk, Suna; Gelincik, Aslı title: Impact of mental health on disease activity in mastocytosis during COVID-19 pandemic date: 2021-08-09 journal: Allergol Int DOI: 10.1016/j.alit.2021.08.002 sha: 7a99ec9320cbd7f792664746c8aaf540092a7074 doc_id: 862897 cord_uid: 74htgl2f Background Mast cell-related symptoms might be influenced by mental health status in mastocytosis. In this study, we aimed to investigate the influence of mental health problems developed during the COVID-19 pandemic on the course of mastocytosis. Methods Mental health status in 60 adult patients with mastocytosis was prospectively evaluated with the total Depression-Anxiety-Stress Scale (tDASS-21) and Fear of COVID-19 Scale (FCV-19S) in the lockdown period (LP) and the return to normal period (RTNP) during the pandemic. The disease course was assessed from emergency and outpatient medical reports, including Scoring Mastocytosis (SCORMA) index and serum baseline tryptase levels, by telephone interviews and clinical visits. Results The mean FCV-19S and median tDASS-21 scores were significantly higher in LP than RTNP (p<0.001) and there was a positive correlation between FCV-19S and tDASS-21 in LP (r=0.820, p<0.001) and in RTNP (r=0.572 p= <0.001). Disease-related symptoms including skin lesions, flushing and anaphylaxis attacks increased in 22 patients in LP, and in this group, mean FCV-19S and median tDASS-21 were higher than those without symptom exacerbation (p<0.001). During the study period, four (6.7%) patients who experienced COVID-19 recovered without any requirement for hospitalization and had not experienced symptom exacerbation. Conclusions Fear of COVID-19 can be a reason for mental health changes, including depression, anxiety and stress which may further increase mast cell-related symptoms. Therefore, psychological support is important to control the severity of mastocytosis during a pandemic. pandemic-related social life 6-9 . It is a matter of concern that patients with chronic diseases can 75 be more affected by this situation. In recent studies, the impact of COVID-19 on patients with 76 chronic diseases has been reported 6-8 , however, there is no data about the psychological effects 77 of the pandemic on symptoms of mastocytosis. 78 Mastocytosis is a rare heterogeneous disease characterized by abnormal proliferation and 79 accumulation of mast cells in different organs 10 . Depending on the mediators released from 80 mast cells (MCs) 11 , clinical symptoms can vary from flushing to severe anaphylaxis 12 . Although 81 most MC-related symptoms can occur spontaneously in mastocytosis, insects can be a common 82 etiologic factor of anaphylaxis 13 . Furthermore, it has been reported in mice and human studies 83 that psychological and environmental stress can cause an increase in MC-related symptoms 14 . 84 Interestingly, in a study, stress by stimulating coronary MCs has been shown to induce or 85 worsen coronary artery diseases 15 . However, there is limited data that show the impact of mental 86 health problems on MC mediator-related symptoms in patients with mastocytosis 14, 16, 17 . 87 By the onset of the COVID-19 pandemic, many people with chronic diseases have been 88 declared as risky groups for a more severe COVID-19 18 anaphylaxis attacks were also invited to the clinic and questioned in terms of triggers, attack 117 numbers, intervention and emergent medications. Also, medical records of emergency room 118 applications were reviewed. Those only experiencing a sensation of flushing were asked to take 119 photographs when they felt flushing to be evaluated by the physicians in the clinic afterwards. In addition, if patients had COVID-19 during the study period, they were evaluated in terms of Table 3 . While more patients had normal mental health status or mild mental health findings 171 in the RTNP, the number of patients with moderate to severe mental health findings was higher 172 in the LP (Table 3) . Table 4 for p values). Table 6 . In the current study, we determined that depression, anxiety and stress levels are higher in 19, it has also seen in healthy individuals 30 . In Turkey, it has been reported that increased 254 depression and anxiety frequencies were detected in healthy population during the pandemic 31 . Although we have no data about the mental health status of our mastocytosis patients before 256 the pandemic, according to these findings, we can speculate that anxiety, depression and stress Our study has several limitations. First, we could not evaluate the mental health status of our 297 patients with the same scales in the pre-pandemic period, which restricted us from reaching 298 more accurate conclusions. However, by excluding those taking psychiatric medications and 299 those having psychiatric diagnoses, we believe that we have increased the strength of our 300 findings. Furthermore, all the patients recovered during the RTNP without applying to a 301 psychiatrist or consuming psychiatric medications during strict social restrictions so that we 302 can assume that the deterioration in mental health status was possibly related to the pandemic 303 rather than the disease itself. A second limitation is that we could not have confirmed the COVID-19: Unanswered questions on immune response 328 and pathogenesis Molecular mechanisms and epidemiology of COVID-19 330 from an allergist's perspective Risk and 332 management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) 333 pandemic: Expert opinions World Health Organization. WHO characterizes COVID-19 as a pandemic COVID-19 Information Platform Psychological Impacts of the COVID-19 Pandemic 340 on the Public in Egypt The outbreak of COVID-19 coronavirus and its impact on global mental health Mental health and the Covid-19 pandemic Depression and anxiety in Hong Kong during COVID-19 Anaphylaxis: Turkish 348 National Guideline New 350 developments in the field of mastocytosis and mast cell activation syndromes: a summary of 351 the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) Idiopathic anaphylaxis yardstick: 354 Practical recommendations for clinical practice Idiopathic anaphylaxis: a form of mast cell activation 357 syndrome COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation Stress triggers 362 coronary mast cells leading to cardiac events Mast cells' involvement in inflammation pathways linked to depression: evidence in 366 mastocytosis Theoharides TC. The impact of psychological stress on mast cells Characteristics of and important lessons from the Coronavirus 370 Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the 371 Chinese Center for Disease Control and Prevention Kontrollü Sosyal Hayat 2020 Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity 377 parameters in childhood and adult cutaneous mastocytosis The psychometric properties of Turkish version of Depression Anxiety Stress 379 7%) Education Not going to school (n,%) Primary school (n,%) High school (n,%) University (n,%) ,%) Active work (n,%) Flexible work (n,%) Housewife (n,%) Salary without work (n,%) Retired (n,%) Fired (n,%) 7 (11.7%) 23 (38.3%) 19 (31.7%) 6 (10%) 3 (5%) 2 (2%) Comorbid diseases Diabetes mellitus (n,%) Hypertension (n,%) Hyperlipidemia (n,%) Hypothyroidism IQR25-75) 25.7 (12.65-38.55) Regular visit to hospital for follow-up in LP (n,%) 6 (10%) Regular visit to hospital for follow J o u r n a l P r e -p r o o f Age (years, mean±SD) 43.60±9.90 Gender J o u r n a l P r e -p r o o f